Skip to main content
PMC Canada Author Manuscripts logoLink to PMC Canada Author Manuscripts
. Author manuscript; available in PMC: 2013 Mar 2.
Published in final edited form as: Br J Sports Med. 2010 Sep 28;45(6):465–467. doi: 10.1136/bjsm.2010.077446

Why so negative about preventing cognitive decline and dementia? - The jury has already come to the verdict for physical activity and smoking cessation

Leon Flicker 1, Teresa Liu Ambrose 2, Arthur F Kramer 3
PMCID: PMC3586248  CAMSID: CAMS2562  PMID: 20876588

The world is ageing rapidly and accompanying this demographic transition will be a significant increase in the number of people with dementia, a condition that will more greatly affect the developing world, rather than the developed world, in both absolute numbers and proportionate increase.[1] The human and financial costs of this condition have, not surprisingly, been of concern to older people, their families and policy makers around the world as they grapple with what will eventually be a major cause of life years lost to disability. The search is on for safe, effective and hopefully, affordable ways to prevent this common and devastating condition of older people.

Against this background, it was timely for the U.S. Department of Health and Human Services National Institutes of Health to host a consensus conference on “Preventing Alzheimer’s Disease and Cognitive Decline”,[2] supported by an Evidence Based Review.[3] Many of the other scourges of old age have already demonstrated a reduction in age specific incidence and thus there is hope that similar outcomes may be achieved for dementia. For example, there has been a 25% reduction in age-adjusted stroke death rates in the United States,[4] an observation confirmed in Australia where further data indicate that this is more likely to be due to a decreased incidence of stroke rather than an improvement in survival following a stroke.[5] Similarly, after an earlier increase, age adjusted female hip fracture incidence decreased between 1995 and 2005 by about 25%.[6] Therefore, prevention of these common problems of older people may be achievable and a goal for which it is worth striving. The degree of difficulty in ascertaining the population prevalence and incidence of dementia, and also that many of the higher quality studies were completed over two decades ago, makes it unlikely that any secular trend in incidence of dementia would have been detected. The fact that we are uncertain as to exactly why the incidence of stroke and hip fractures has decreased has not deterred the ongoing search for modifiable risk factors and interventions in these conditions, and nor should it in the commonest cause of severe disability in older people - dementia.

So what were the conclusions of this consensus conference? Not a lot. Firstly, the title of the conference was a little disappointing in itself as all that is dementia is not Alzheimer’s Disease (AD), particularly in the very old.[7] As growing numbers of people of advanced age underly the large increase in the number of people with dementia, it is likely that the proportion of people with dementia due to AD will decrease in the future, and many of these people with dementia will have mixed pathology. One of the criticisms the consensus panel leveled at the vascular risk factor hypothesis was “it can be quite difficult to disentangle the factors associated with Alzheimer’s disease because of their contribution to vascular disease and related dementias and those that are truly associated with Alzheimer’s disease”. Surely with our increased understanding of the role of vascular factors in the progression of AD this is putting too fine a point on this issue. The more important question is whether the treatment of vascular factors results in decreased rates of dementia, including AD and the amount of cognitive decline. The best evidence for treatment of vascular risk factors lies in the use of anti-hypertensives where there is considerable uncertainty as to what the RCT evidence already has demonstrated but the comment from the Evidence Based Review[3] appeared far too negative. A recent systematic review[8] which included one additional randomized trial to the Cochrane meta-analysis[9] demonstrated a 13% reduction in the rate of incident dementia with the use of antihypertensives. This may be the best evidence that we will ever obtain on this subject due to the bias to the null hypothesis because of the large number of control subjects who require treatment with antihypertensives, and the experience from the HYVET study[10] that these trials are no longer able to be performed in the developed world because of the understandable reluctance of clinicians to randomize hypertensive older people to placebo, when effective antihypertensives are readily available.

Perhaps the most worrying part of the consensus statement concerned the very negative view of the effect of modifiable lifestyle factors, for two of which there is already good evidence for individuals to make judgments. The first of these is smoking. Initially smoking, based on case control studies, was considered a protective factor for the development of AD but a review of the cohort studies found an elevated risk.[11] This finding is supported by a recent systematic review [12] of cohort studies which demonstrated an increased risk of 1.79 (95% CI 1.43–2.23) for incident AD. In addition brain imaging has provided confirmatory evidence. In a study examining older smokers without discernible cognitive changes, smokers were found to have decreased grey matter density in the posterior cingulate and precuneus, right thalamus and frontal cortex compared with non-smokers, similar abnormalities to those found in people with early AD.[13] Because of ethical concerns, there will be no randomized trials evaluating this risk factor, but AD, and a multitude of other diseases, can have their incidence decreased by quitting smoking. It is difficult to dismiss this evidence, as the NIH statement does, as being “of low quality”.

The evidence for physical activity seemed also to be discounted too cursorily for what is now a large and relatively consistent pool of animal and human data. Animal studies support the concept of plasticity of the human brain and that many molecular and cellular pathways may be involved in neurogenesis and other exercise induced structural and functional brain changes. [14,15] Observational data across the life course support the benefits of physical activity, particularly aerobic activity in improving cognition.[16] There are even more data than the Evidence Based Review mentioned. The Duke Team[3] who reviewed 12 cohort studies and found that physical activity lowered the risk by 30% of incident AD. A recent review summarized observational data of 14 studies, contained data on 27,255 participants of which 2731 had a diagnosis of dementia or AD.[17] The pooled relative risk for overall dementia in the highest physical activity category compared with the lowest was 0.72 (95% CI 0.60–0.86), and for AD 0.55 (95% CI 0.36–0.84). These observational data are very consistent with a lowering of risk with increased physical activity, but because reverse causality may be an issue, i.e. those people who are in better cognitive health may choose greater levels of physical activity, confirmation by randomized trials is essential.

Ideally trials of increased physical activity should be examined against the outcome of incident AD but no such studies exist, and they would by necessity require large numbers, for a prolonged period of follow-up, and therefore be very expensive. However, there are now many trials of physical activity in humans with a diverse range of cognitive outcomes and a more modest set of brain changes. Besides the Cochrane review[18] referred to in the Evidence Based Review there have been other reviews which have included other studies which also find cognitive benefits. [16] The Cochrane review found improvements in motor function and auditory attention in the groups randomized to aerobic physical activity whereas other reviews have found benefits in executive functions.[19] There have been several other recent RCTs only one of which[20] was identified by the Evidence Based Review. That study examined 170 participants with memory complaints who were randomized to a 24-week home-based program of physical activity. Participants in the intervention group improved 1.3 points (95% confidence interval, (CI) −2.38 to −0.22) on the main outcome measure of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and this improvement was maintained for 12 months after the completion of the intervention with some other benefits demonstrated in memory. Another study of aerobic exercise in subjects with mild cognitive impairment aged 70 to 80 years found trends for effects in improving memory and attention over a 12 months period.[21] Another moderately large study of progressive resistance training has added further complexity to these issues.[22] This study found benefits in women aged 65 to 75 years of age with training designed to increase strength as opposed to aerobic ability. These cognitive benefits were mainly found in executive functioning. Other randomized controlled trials have found benefits in brain structure and function as well as improvements in cognition as a function of 6 and 12 month aerobic training programs.[2325]

Thus there is now good evidence that the use of antihypertensive medication, cessation of smoking and increasing physical activity produce cognitive benefits in older people. Because of ethical concerns randomization to control groups are already difficult to perform for trials of antihypertensive medications and quitting smoking. The evidence for increased physical activity spans animal studies, observational and randomized trials in humans and the evidence is quite consistent. In a country which has deemed boldness to be a virtue, it is difficult to understand why the NIH consensus statement has taken such a cautious approach.

Footnotes

Copyright:

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BJSM editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-for-authors/licence-forms/).

Competing Interest: None to declare

Contributor Information

Leon Flicker, Director, Western Australian Centre for Health and Ageing, Centre for Medical Research, Western Australian Institute for Medical Research, Professor of Geriatric Medicine, School of Medicine and Pharmacology, University of Western Australia.

Teresa Liu Ambrose, Department of Physical Therapy, University of British Columbia, Brain Research Centre, University of British Columbia, Centre for Hip Health and Mobility, University of British Columbia.

Arthur F Kramer, Director, Beckman Institute for Advanced Science & Technology, Swanlund Professor of Psychology & Neuroscience, University of Illinois.

References

  • 1.Ferri CP, Prince M, Brayne C, et al. Alzheimer’s Disease International Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–7. doi: 10.1016/S0140-6736(05)67889-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.NIH State-of-the-Science Conference Preventing Alzheimer’s Disease and Cognitive Decline; April 26–28, 2010; Bethesda, Maryland . http://consensus.nih.gov/2010/alzstatement.htm. [Google Scholar]
  • 3.Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer’s Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193. AHRQ Publication No. 10-E005. Rockville, MD: Agency for Healthcare Research and Quality; Apr, 2010. http://www.ahrq.gov/clinic/tp/alzcogtp.htm. [PMC free article] [PubMed] [Google Scholar]
  • 4.Towfighi A, Ovbiagele B, Saver JL. Therapeutic milestone: stroke declines from the second to the third leading organ- and disease-specific cause of death in the United States. Stroke. 2010;41:499–503. doi: 10.1161/STROKEAHA.109.571828. [DOI] [PubMed] [Google Scholar]
  • 5.Islam MS, Anderson CS, Hankey GJ, et al. Trends in incidence and outcome of stroke in Perth, Western Australia during 1989 to 2001: the Perth Community Stroke Study. Stroke. 2008;39:776–82. doi: 10.1161/STROKEAHA.107.493643. [DOI] [PubMed] [Google Scholar]
  • 6.Brauer CA, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302:1573–9. doi: 10.1001/jama.2009.1462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Savva GM, Wharton SB, Ince PG, et al. Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302–9. doi: 10.1056/NEJMoa0806142. [DOI] [PubMed] [Google Scholar]
  • 8.Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial Cognitive Function Assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683–9. doi: 10.1016/S1474-4422(08)70143-1. [DOI] [PubMed] [Google Scholar]
  • 9.McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(4):CD004034. doi: 10.1002/14651858.CD004034.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98. doi: 10.1056/NEJMoa0801369. [DOI] [PubMed] [Google Scholar]
  • 11.Almeida OP, Hulse GK, Lawrence D, et al. Smoking as a risk factor for Alzheimer’s disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction. 2002;97:15–28. doi: 10.1046/j.1360-0443.2002.00016.x. [DOI] [PubMed] [Google Scholar]
  • 12.Anstey KJ, von Sanden C, Salim A, et al. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367–78. doi: 10.1093/aje/kwm116. [DOI] [PubMed] [Google Scholar]
  • 13.Almeida OP, Garrido GJ, Lautenschlager NT, et al. Smoking is associated with reduced cortical regional gray matter density in brain regions associated with incipient Alzheimer disease. Am J Geriatr Psychiatry. 2008;16:92–8. doi: 10.1097/JGP.0b013e318157cad2. [DOI] [PubMed] [Google Scholar]
  • 14.Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464–472. doi: 10.1016/j.tins.2007.06.011. [DOI] [PubMed] [Google Scholar]
  • 15.Vaynman S, Gomez-Pinilla F. Revenge of the “sit”: How lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity. J Neurosci Res. 2006;84:699–715. doi: 10.1002/jnr.20979. [DOI] [PubMed] [Google Scholar]
  • 16.Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nature Rev Neurosci. 2008;9:58–65. doi: 10.1038/nrn2298. [DOI] [PubMed] [Google Scholar]
  • 17.Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med. 2009;39:3–11. doi: 10.1017/S0033291708003681. [DOI] [PubMed] [Google Scholar]
  • 18.Angevaren M, Aufdemkampe G, Verhaar HJJ, et al. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev. 2008;(3):Art. No.: CD005381. doi: 10.1002/14651858.CD005381.pub3. [DOI] [PubMed] [Google Scholar]
  • 19.Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci. 2003;14:125–130. doi: 10.1111/1467-9280.t01-1-01430. [DOI] [PubMed] [Google Scholar]
  • 20.Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300:1027–37. doi: 10.1001/jama.300.9.1027. [DOI] [PubMed] [Google Scholar]
  • 21.van Uffelen JG, Chinapaw MJ, van Mechelen W, et al. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med. 2008;42:344–351. doi: 10.1136/bjsm.2007.044735. [DOI] [PubMed] [Google Scholar]
  • 22.Liu-Ambrose T, Nagamatsu LS, Graf P, et al. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med. 2010;170:170–178. doi: 10.1001/archinternmed.2009.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA. 2004;101:3316–3321. doi: 10.1073/pnas.0400266101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci. 2006;61:1166–1170. doi: 10.1093/gerona/61.11.1166. [DOI] [PubMed] [Google Scholar]
  • 25.Voss M, Prakash R, Erickson K, et al. Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Front Aging Neurosci. doi: 10.3389/fnagi.2010.00032. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES